Core Viewpoint - A securities class action has been filed against Telix Pharmaceuticals Ltd. for alleged violations of the Securities Exchange Act of 1934, with a class period from February 21, 2025, to August 28, 2025, and investors have until January 9, 2026, to seek appointment as lead plaintiff [1]. Allegations - The lawsuit alleges that Telix and its executives overstated progress on the company's prostate cancer therapeutic candidates [6]. - The company is also accused of overstating the quality of its supply chain and partner operations [6]. Key Events - On February 20, 2025, Telix held an earnings call where executives claimed significant progress in their therapeutic pipeline, particularly in prostate cancer, which was said to be in Phase 3 [6]. - On July 22, 2025, Telix reported to the SEC that it received a subpoena regarding its prostate cancer therapeutic candidates, leading to a 16% drop in share price, the largest decline in 21 months [6]. - Following the subpoena news, Telix ADSs fell by $1.70 (10.4%) to close at $14.58 on July 23, 2025, and further dropped by $0.69 (4.7%) to close at $13.89 on July 24, 2025 [6]. - On August 28, 2025, Telix announced that the FDA issued a Complete Response Letter for its renal cancer drug candidate, resulting in a $1.95 (16.1%) drop in share price to close at $10.15 [6]. - The following day, Telix ADSs fell an additional $0.60 (5.9%) to close at $9.55 on August 29, 2025 [6].
Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately